Torrent Sees Decline In US Sales After Dropping Sartan Portfolio
As Company Continues To Grow Domestically
Torrent Pharma has reported a double-digit drop in its US revenues after discontinuing its sartan portfolio, due to the presence of trace amounts of N-nitrosodimethylamine. The company saw its domestic market grow aided by market share gains in high potential new launches.
